New ‘Star Wars’ gaming package makes retail debut
SAN DIEGO and SAN FRANCISCO Avid "Star Wars" fans and game enthusiasts rejoice: "Star Wars: Clone Wars Adventures Galactic Passport" has hit retail.
The "Star Wars: Clone Wars Adventures Galactic Passport" package includes a 90-day premium Jedi membership, 500 Station Cash, the exclusive Togruta playable character species, a Yoda bobblehead monitor topper, additional digital content and more.
"Star Wars: Clone Wars Adventures Galactic Passport" was developed and published by Sony Online Entertainment through an agreement with LucasArts, a division of Lucasfilm.
“With the launch of ‘Clone Wars Adventures Galactic Passport’ at retail, we are able to offer fans a mix of real-world and virtual world content to enjoy and enhance their gameplay,” said John Smedley, president of Sony Online Entertainment. “With the holiday season right around the corner, the Galactic Passport and Yoda bobblehead will make great stocking stuffers for ‘Star Wars’ fans of all ages.”
Big Y finalizing purchase of Conn.-based A&P stores
SPRINGFIELD, Mass. Big Y reportedly is closing its deal to acquire seven A&P stores in northern Connecticut.
The Springfield, Mass.-based retailer said the sale will be completed on Nov. 1, according to the Boston Herald. Big Y owns stores in Massachusetts and Connecticut and has served these markets for nearly 75 years.
As previously reported by Drug Store News, grocer A&P announced in September an agreement with Big Y to sell the stores as part of its turnaround strategy.
“We continue to evaluate our operating footprint and its alignment with our turnaround strategy. These seven stores were clearly outside of our core markets, and their sale was necessary,” Sam Martin, president and CEO of A&P, stated at the time.
NeurogesX seeks expanded approval for Qutenza
SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.
NeurogesX announced Monday that it would seek Food and Drug Administration approval for the drug Qutenza (capsaicin) as a treatment for HIV-associated neuropathy, also called HIV-AN or HIV-distal sensory polyneuropathy, in the first half of 2011. The drug, a patch, already is approved for post-herpetic neuralgia. HIV-AN results from injury to sensory neurons by HIV virus proteins, the body’s immune response to the virus and some drugs used to treat it.
“As a company, we are focused on addressing unmet medical needs in pain and have made significant progress toward this goal with the U.S. launch of Qutenza,” NeurogesX president and CEO Anthony DiTonno said. “Our decision to submit a supplemental [application] to address the HIV-AN patient population is important as there are currently no FDA-approved treatments for HIV-AN.”